Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2
Denis Riendeau(United States Nuclear Regulatory Commission), M. David Percival(United States Nuclear Regulatory Commission), Christine Brideau(United States Nuclear Regulatory Commission), S. Charleson(United States Nuclear Regulatory Commission), Daniel Dubé(United States Nuclear Regulatory Commission), Diane Ethier(United States Nuclear Regulatory Commission), Jean‐Pierre Falgueyret(United States Nuclear Regulatory Commission), Richard W. Friesen(United States Nuclear Regulatory Commission), Robert J. Gordon(United States Nuclear Regulatory Commission), Gillian Greig(United States Nuclear Regulatory Commission), Jocelyne Guay(United States Nuclear Regulatory Commission), Joseph A. Mancini(United States Nuclear Regulatory Commission), Marc Ouellet(United States Nuclear Regulatory Commission), Elizabeth Wong(United States Nuclear Regulatory Commission), Li Xu(United States Nuclear Regulatory Commission), S. Boyce(United States Nuclear Regulatory Commission), Denise M. Visco(United States Nuclear Regulatory Commission), Yves Girard(United States Nuclear Regulatory Commission), Petpiboon Prasit(United States Nuclear Regulatory Commission), Robert Zamboni(United States Nuclear Regulatory Commission), Ian W. Rodger(United States Nuclear Regulatory Commission), Michael J. Gresser(United States Nuclear Regulatory Commission), A W Ford‐Hutchinson(United States Nuclear Regulatory Commission), Robert N. Young(United States Nuclear Regulatory Commission), Chi‐Chung Chan(United States Nuclear Regulatory Commission)
Cited by 460Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis